

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
28 December 2006 (28.12.2006)

PCT

(10) International Publication Number
WO 2006/136305 A1

(51) International Patent Classification:

C07D 401/06 (2006.01) A61K 31/4015 (2006.01)
 C07D 207/26 (2006.01) A61K 31/4412 (2006.01)
 C07D 275/02 (2006.01) A61P 9/00 (2006.01)
 C07D 409/06 (2006.01) A61P 11/00 (2006.01)
 C07D 401/14 (2006.01) A61P 25/28 (2006.01)
 C07D 211/76 (2006.01) A61P 35/00 (2006.01)

c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **WAGNER, Michael** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **RUXER, Jean-Marie** [FR/FR]; c/o Aventis Pharma, 13, quai Jules Guesde, F-94403 Vitry-sur-Seine Cedex (FR). **PILORGE, Fabienne** [FR/FR]; c/o Aventis Pharma, 13, quai Jules Guesde, F-94403 Vitry-sur-Seine Cedex (FR).

(21) International Application Number:

PCT/EP2006/005579

(22) International Filing Date: 10 June 2006 (10.06.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

10 2005 028 845.6 22 June 2005 (22.06.2005) DE

(71) Applicant (for all designated States except US): **SANOFI-AVENTIS DEUTSCHLAND GMBH** [DE/DE]; Brüningstrasse 50, 65929 Frankfurt am Main (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BRENDEL, Joachim** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **ENGLERT, Heinrich Christian** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **PEUKERT, Stefan** [DE/US]; 19 Albermarle Street, Arlington, MA 02476 (US). **WIRTH, Klaus** [DE/DE];

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED PYRROLIDIN-2-ONES, PIPERIDIN-2-ONES AND ISOTHIAZOLIDINE-1, 1-DIOXIDES, THEIR USE AS K_V1.5 POTASSIUM CHANNEL BLOCKERS AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM



(57) Abstract: The invention relates to compounds of the formula (I), in which A, R₁, R₂, R₃, R₄, R₅, R₆, R₇ and n have the meanings stated in the claims. The compounds are particularly suitable as antiarrhythmic active ingredients, in particular for the treatment and prophylaxis of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.